Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) saw an upside of 5.67% to close Thursday at $1.02 after adding $0.05 on the day. The 5-day average trading volume is 1,433,460 shares of the company’s common stock. It has gained $1.0400 in the past week and touched a new high 1 time within the past 5 days. An average of 1,628,925 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,138,768.
ADMP’s 1-month performance is -11.01% or -$0.0996 on its low of $0.9580 reached on 09/30/21. The company’s shares have touched a 52-week low of $0.38 and high of $2.34, with the stock’s rally to the 52-week high happening on 01/22/21. YTD, ADMP has achieved 99.96% or $0.5253 and has reached a new high 8 times. However, the current price is down -56.20%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Nov 20, 315 days have gone by since the last insider trading activity for Adamis Pharmaceuticals Corporation (ADMP). Marguglio David J. (SVP and Chief Business Officer) most recently sold 35,000 shares at $0.40 per share on Nov 20. This transaction cost the insider $14,000. Chief Financial Officer, Hopkins Robert O, sold 35,000 shares at a price of $0.41 on Nov 20. Then, on Nov 18, Chief Medical Officer Moss Ronald B. sold 8,532 shares at a price of $0.41 per share. This transaction amounted to $3,465.
Adamis Pharmaceuticals Corporation (ADMP) has a trailing price-to-earnings (P/E) ratio of 24.48 for the broader industry and 32.27 for the sector, meaning that investors are optimistic about the stock’s future prospects. ADMP stock has a beta of 1.33. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 8.84 while the price-to-book (PB) in the most recent quarter is 24.25.
Adamis Pharmaceuticals Corporation’s quick ratio for the period ended December 30 was 0.50, with the current ratio over the same period at 0.60 meaning that ADMP stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending December 30 was 0.26, while the total debt to equity was 1.51. In terms of profitability, the gross margin trailing 12 months is 9.90%The trailing 12-month EBITDA margin is -154.59%. The firm’s gross profit as reported stood at $1.63 million against revenue of $16.53 million.
The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Adamis Pharmaceuticals Corporation’s return on assets over the past 12 months stands at -123.70%. Return on investment over the past year is -565.70%, while its return on equity (ROE) trailing 12 months is -226.50%. In comparison, the average ROE for the broader industry over the past year is 4.13.
For the quarterly period ending December 30 this year, Net income and sales went down compared to those figures reported in the previous quarter. Analysts expected ADMP to announce -$0.06 per share in earnings in its latest quarter, but it posted -$0.24, representing a -300.00% surprise. EBITDA for the quarter stood at more than -$13.98 million. ADMP stock balance sheet for the quarter ending December 30 shows that total liabilities totaled 27.37 million, with total debt at $6.86 million. Shareholders hold equity totaling $148.89 million
Let’s look briefly at Adamis Pharmaceuticals Corporation (ADMP) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 44.17% to suggest the stock is trending Neutral, with historical volatility in this time period at 35.83%.
The stock’s 5-day moving average is $0.9923, reflecting a -2.85% or -$0.0296 change from its current price. ADMP is currently trading -11.37% above its 20-day SMA, +41.31% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -4.68% and +97.50% respectively.
Stochastic %K and %D was 12.50% and 7.96% and the average true range (ATR) pointed at 0.0489. The RSI (14) points at 44.97%, while the 14-day stochastic is at 30.47% with the period’s ATR at 0.0543. The stock’s 9-day MACD Oscillator is pointing at -0.0344 and -0.0556 on the 14-day charts.
In the most recent analyst report for Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), Maxim Group upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for ADMP stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate ADMP as a “sell,”, while 1 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is ADMP’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $1.50 and a high of $1.50, with their median price target at $1.50. Looking at these predictions, the average price target given by analysts is for Adamis Pharmaceuticals Corporation (ADMP) stock is $1.50.